New Drug Offer Hope To Patients With Late Stage Prostate Cancer
At present, metastatic and hormonal-refractory prostate cancer patients who have failed 1st line chemotherapy will be given mitoxantrone plus prednisone as the salvage therapy. However, mitoxantrone plus prednisone is not very effective in controlling metastatic prostate cancer. Now, a new drug developed by sanofi-aventis might offer hope to patients who have failed 1st line chemotherapy (docetaxel plus prednisone).
The new drug called cabazitaxel was investigated in the TROPIC trial that included 755 advanced prostate cancer patients who have failed 1st line docetaxel chemotherapy. Half of the patients in the trial received combination of cabazitaxel and prednisone while the other half received mitoxantrone and prednisone.
Related Posts...
The Kanzius Cancer Cure – A Medical Cinderella Story by Mesothelioma Lawyer
Did you ever dream you'd be the one to find the cure for cancer? Probably not.
What Are The Prostate Cancer Symptoms by Mesothelioma Lawyer
The exact cause for prostate cancer is unknown but there are several risk factors which can be observed.


US $9.99






